Literature DB >> 6644376

Factors influencing DTPA conjugation with antibodies by cyclic DTPA anhydride.

C H Paik, M A Ebbert, P R Murphy, C R Lassman, R C Reba, W C Eckelman, K Y Pak, J Powe, Z Steplewski, H Koprowski.   

Abstract

Diethylenetriaminepentaacetic acid (DTPA) was conjugated with a practical concentration (300 micrograms/ml) of antibody to human albumin (Ab) and 1083 17-1A monoclonal colorectal antibody (MAb-17-1A) via an acylation reaction using cyclic DTPA anhydride (cDTPAA). The conjugation reaction was favored as pH increased. Bicarbonate buffer at pH 8.2 was chosen for studies of the effect of the cDTPAA-to-antibody ratio on DTPA conjugation with antibody because of its good buffer capacity at that pH. The reaction of cDTPAA with Ab at molar ratios of 2000, 1000, 500, and 100 in the bicarbonate buffer gave rise to 11, 9, 8, and 2 indium atoms incorporated per Ab with 47%, 55%, 59%, and 77% retention of the binding activity. For the conjugation reaction of MAb-17-1A, 29, 28, 31, 11, 4, and 1 indium atoms were incorporated, with the retention of less than 5%, less than 5%, less than 5%, 12%, 60%, and 93% of binding activity when the molar ratio was 5000, 2000, 1000, 500, 100, and 50.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6644376

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

1.  Effect of isoelectric point on biodistribution and inflammation: imaging with indium-111-labelled IgG.

Authors:  C I ten Kate; A J Fischman; R H Rubin; A J Fucello; D Riexinger; R A Wilkinson; L Du; B A Khaw; H W Strauss
Journal:  Eur J Nucl Med       Date:  1990

Review 2.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 3.  Approaches to radiolabeling of antibodies for diagnosis and therapy of cancer.

Authors:  A R Fritzberg; R W Berninger; S W Hadley; D W Wester
Journal:  Pharm Res       Date:  1988-06       Impact factor: 4.200

4.  Radiolabelling of monoclonal antibodies: optimization of conjugation of DTPA to F(ab')2-fragments and a novel measurement of the degree of conjugation using Eu(III)-labelling.

Authors:  M Hartikka; P Vihko; M Södervall; L Hakalahti; P Torniainen; R Vihko
Journal:  Eur J Nucl Med       Date:  1989

Review 5.  Techniques for molecular imaging probe design.

Authors:  Fred Reynolds; Kimberly A Kelly
Journal:  Mol Imaging       Date:  2011-12       Impact factor: 4.488

6.  Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.

Authors:  In Soo Shin; Sang-Myung Lee; Hyung Sub Kim; Zhengsheng Yao; Celeste Regino; Noriko Sato; Kenneth T Cheng; Raffit Hassan; Melissa F Campo; Earl F Albone; Peter L Choyke; Ira Pastan; Chang H Paik
Journal:  Nucl Med Biol       Date:  2011-07-07       Impact factor: 2.408

7.  Polyclonal 111In-IgG, 125I-LDL and 125I-endothelin-1 accumulation in experimental arterial wall injury.

Authors:  L Prat; G Torres; I Carrió; M Roca; V Riambau; L Berná; M Estorch; I Ferrer; C García
Journal:  Eur J Nucl Med       Date:  1993-12

8.  Labeling of monoclonal antibodies with a 67Ga-phenolic aminocarboxylic acid chelate. Part I. Chemistry and labeling technique.

Authors:  J Schuhmacher; R Matys; H Hauser; W Maier-Borst; S Matzku
Journal:  Eur J Nucl Med       Date:  1986

9.  Comparison of the distribution and binding of monoclonal antibodies labeled with 131-iodine or 111-indium.

Authors:  D Buchsbaum; B Randall; D Hanna; R Chandler; M Loken; E Johnson
Journal:  Eur J Nucl Med       Date:  1985

10.  Radioimmunoscintigraphy of xenografted human thyroid carcinoma.

Authors:  K Koizumi; K Yokoyama; N Watanabe; S Kawabata; N Shuke; S Kinuya; T Aburano; N Tonami; K Hisada; N Sato
Journal:  Ann Nucl Med       Date:  1988-05       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.